The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session

Results: Overall outcomes for the whole series at 6 years are comparable between haplo-cord and UD-controls for non-relapse mortality (33.0%, 95CI: 24.7–44.0 versus 34.4%, 95CI: 28.1–42.0, respectively; n.s.), and show a statistical trend in favour of haplo-cord in relapse rate (24.5%, 95CI:17.2–34.9 in haplo-cord versus 30.7%, 95CI:24.7–38.2 in UD-controls; p = 0.135) and overall survival (47.7%, 95CI: 37.6–57.8 in haplo-cord versus 37.0%, 95CI: 29.9–44.0 in UD-controls; p = 0.079).In addition, grade II-IV acute GvHD was significantly lower in the haplo-cord group (12.1% vs 40.7%, p = 0.001; 35.8% in matched vs 45.6% in mismatched controls) as well as chronic GvHD (29.9% vs 50.0%, p = 0.02; 43.6% in matched vs 55.8% in mismatched controls).

also in 2,798 other papers

By comparison, CD19+CD21 Low B cells were proportionally higher in the cGVHD group, although this did not reach statistical significance.

also in 111,027 other papers